20/20 Biolabs, Inc. — Form 8-K
Filed July 22, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
On July 16, 2026, 20/20 Biolabs entered into a standstill agreement with Streeterville Capital, LLC, its Series E preferred shareholder (from a November 17, 2025 investment). Streeterville Capital agrees to refrain from converting Series E Preferred Stock into Common Stock for 120 days, except if common shares trade at least 10% above the Nasdaq Minimum Price. The standstill terminates immediately upon any breach or Event of Default, after which Streeterville may convert without the 10% price restriction. No cash or property changed hands for this agreement.
Why this rating
Standstill is defensive protection for the company preventing dilution for 120 days; typical preferred-stock governance mechanism. Relative to $5.8M asset company, it provides modest breathing room but does not materially alter business trajectory or financial position.
See more from July 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.